FDA Approves Johnson & Johnson Psoriasis Drug ICOTYDE

J&J reports results from ICONIC 52-week trials of Icotyde

J&J has reported new 52-week data from the Phase III ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and ICONIC-LEAD trials, evaluating the safety and efficacy of Icotyde, a once-daily oral pill for moderate-to-severe plaque psoriasis.The post J&J reports results from ICONIC 52-week trials of Icotyde appeared first on Clinical Trials Arena.

FDA Approves Johnson & Johnson Psoriasis Drug ICOTYDE

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients age 12 and older who weigh at least 40 kilograms. The drug is an oral interleukin-23 receptor antagonist intended for patients eligible for systemic therapy or phototherapy, offering a once-daily treatment option. The approval is ba…